IP Library Granted Patent US 7,429,578
Granted Patent B2
US 7,429,578 · App. 11/221,245 · Granted Sep 30, 2008

Tricyclic inhibitors of poly(ADP-ribose) polymerases

Assignees: Agouron Pharmaceuticals, Inc.; Cancer Research Campaign Technology Limited
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,429,578
App. No.
11/221,245
Granted
Sep 30, 2008
Kind
B2
Abstract

Compounds of the formula below are poly(ADP-ribosyl)transferase (PARP) inhibitors, and are useful as therapeutics in treatment of cancers and the amelioration of the effects of stroke, head trauma, and neurodegenerative disease. As cancer therapeutics, the compounds of the invention may be used, e.g., in combination with cytotoxic agents and/or radiation.

Claims (29)

1. A method of potentiating cytotoxicity of a DNA-damaging cytotoxic agent or ionizing radiation, comprising contacting cells with an effective amount of a compound of formula (I):

wherein:

R 1 is: H;

halogen;

cyano;

an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; or

—C(O)—R 10 , where R 10 is: H; an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; or OR 100 or NR 100 R 110 , where R 100 and R 110 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group

R 2 is H or alkyl;

R 3 is H or alkyl;

R 4 is H, halogen or alkyl;

X is O or S;

Y is (CR 5 R 6 )(CR 7 R 8 ) n or N═C(R 5 ), where:

n is 0 or 1;

R 5 and R 6 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group; and

R 7 and R 8 are each independently H or an optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl group;

wherein said optional substitutions are selected from the group consisting of hydroxy, F, Cl, I, Br, oxo, alkyl, acyl, sulfonyl, mercapto, nitro, alkylthio, alkoxy, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, carboxy, primary amino, secondary amino, tertiary amino, carbamoyl, aryloxy, heteroaryloxy, arylthio, and heteroarylthio;

or a pharmaceutically acceptable salt thereof, in combination with the DNA-damaging cytotoxic agent or ionizing radiation.

2. The method of claim 1 wherein in the compound of formula (I) or salt thereof, wherein:

Y is (CR 5 R 6 )(CR 7 R 8 ) n , where:

n is 1;

R 5 , R 6 , R 7 and R 8 are H.

3. The method of claim 2 wherein in the compound of formula (I) or salt thereof, wherein:

R 1 is 4-methylaminomethyl-phenyl;

R 2 is H;

R 3 is H;

R 4 is 8-fluoro;

X is O.

4. The method of claim 1 wherein the compound of formula (I) or salt thereof has a cytotoxicity potentiation activity corresponding to a PF 50 of at least 1.1 in a cytotoxicity potentiation assay.

5. The method of claim 1 wherein the compound of formula (I) or salt thereof has a cytotoxicity potentiation activity corresponding to a PF 50 of from about 1.1 to about 3 in a cytotoxicity potentiation assay.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 22, 2018
From: WEBBER, STEPHEN EVAN; CANAN-KOCH, STACIE S.; TIKHE, JAYASHREE; THORESEN, LARS HENRIK
To: AGOURON PHARMACEUTICALS, INC.; CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
Reel/Frame 047259/0498 →
CHANGE OF NAME Recorded Mar 8, 2016
From: AGOURON PHARMACEUTICALS, INC.
To: AGOURON PHARMACEUTICALS, LLC
Reel/Frame 038033/0099 →
CHANGE OF NAME Recorded Mar 8, 2016
From: CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED
To: CANCER RESEARCH TECHNOLOGY LIMITED
Reel/Frame 038033/0430 →
Continuity (6)
Continuation 1100426100 · Dec 3, 2004
Continuation 1094997600 · Nov 9, 2004
Continuation 1026401800 · Oct 2, 2002
Continuation 0947989600 · Jan 10, 2000
Provisional Application 6011543100 · Jan 11, 1999
Related Publication 20060009517A1 · Jan 12, 2006